Global Market Report

Spinal Muscular Atrophy (SMA) Market Report 2020-2030

Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level.

SKU: PHA0597 Category: Tag: Code: PHA0597
Clear
โ† Back to category Therapeutic Drugs

Description

Our 150+ page report provides 90 tables, 48 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Spinal Muscular Atrophy (SMA) market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
– You find original analyses, with business outlooks and developments.
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 3 segmentations of the Spinal Muscular Atrophy (SMA) market, with forecasts for 4 Disease, 2 Treatment, 2 Route of Administration, each forecasted at a global and regional level.

Global Spinal Muscular Atrophy (SMA) Market by Disease
– Type 1
– Type 2
– Type 3
– Type 4

Global Spinal Muscular Atrophy (SMA) Market by Treatment
– Gene Therapy
– Drug
– RG6083
– RG7916
– Spinraza

Global Spinal Muscular Atrophy (SMA) Market by Route of Administration
– Oral
– Intrathecal

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

– North America:
– US
– Canada

– Europe:
– Germany
– France
– UK
– Italy
– Spain
– Russia
– Rest of Europe

– Asia-Pacific:
– Japan
– China
– India
– Australia
– ASEAN
– Rest of Asia-Pacific

– Latin America:
– Brazil
– Mexico
– Rest of Latin America

– MEA:
– UAE
– South Africa
– Saudi Arabia
– Rest of MEA

The report also includes profiles and for some of the leading companies in the Spinal Muscular Atrophy (SMA) Market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Japan, India and China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth
Overall world revenue for Spinal Muscular Atrophy (SMA) will surpass $950 mn in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Spinal Muscular Atrophy (SMA) Market report helps you

In summary, our 150+ page report provides you with the following knowledge:

– Revenue forecasts to 2030 for 3 segmentations of the Spinal Muscular Atrophy (SMA) market, with forecasts for 4 Disease, 2 Treatment, 2 Route of Administration, each forecasted at a global and regional level,discover the industry’s prospects, finding the most lucrative places for investments and revenues
– Revenue forecasts to 2030 for 5 regional and 18 key national markets , See forecasts for the Spinal Muscular Atrophy (SMA) market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, ASEAN countries, UAE, South Africa and Saudi Arabia.
– Stimulates and restrains companies and the market
– Prospects for established firms and those seeking to enter the market, including company profiles for 11 of the major companies involved in the Spinal Muscular Atrophy (SMA) market
– Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain study is for everybody needing commercial analyses for the Spinal Muscular Atrophy (SMA) market and leading companies. You will find data, trends and predictions.
Get our report today The Spinal Muscular Atrophy (SMA) Market Forecast 2020-2030: Revenue Prospects by Disease (Type 1, Type 2, Type 3, Type 4), Treatment {Gene Therapy, Drug (RG6083, RG7916, Spinraza)}, Route of Administration (Oral, Intrathecal) and Geography.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1 Global Spinal Muscular Atrophy (SMA) Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Includes
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction
2.1 Objectives of the Study
2.2 Market Definition
2.3 Market Scope
2.4 Markets Covered
2.5 Years Considered for the Study
2.6 Limitations
2.7 Currency

3. Industry Insights
3.1 Market Drivers
3.1.1 Rising importance of rare diseases
3.1.2 Increasing initiatives for creating awareness of SMA
3.1.3 Growing research initiatives by market players for developing treatment for SMA
3.2 Market Restraints
3.2.1 Limited access to treatment of SMA
3.2.2 High costs of treatment
3.2.3 Lack of experienced professionals
3.2.4 Low adoption rate of SMA treatment options
3.3 Value chain analysis
3.4 SWOT analysis (qualitative insights)
3.4.1 Sources of strengths which could be leveraged
3.4.2 Weaknesses to overcome & offset
3.4.3 Opportunities to capitalize upon
3.4.4 Threats to mitigate
3.5 PEST analysis (qualitative insights)
3.5.1 Political factors
3.5.2 Economic factors
3.5.3 Social factors
3.5.4 Technological factors
3.6 Porters Five Forces Model (qualitative insights)
3.6.1 Threat of New Entrants
3.6.1.1 Barriers to entry
3.6.1.2 Economies of scale
3.6.1.3 Brand loyalty
3.6.1.4 Switching costs
3.6.1.5 Government policies
3.6.2 Bargaining Power of Buyers
3.6.2.1 Buyer concentration to firm concentration ratio
3.6.2.2 Buyer switching costs relative to firm switching costs
3.6.2.3 Degree of dependency upon existing channels of distribution
3.6.2.4 Buyer's information availability
3.6.3 Threat of Substitutes
3.6.3.1 Number of substitute products available
3.6.3.2 Buyer propensity to substitute
3.6.3.3 Relative price performance of substitute
3.6.4 Bargaining Power of Suppliers
3.6.4.1 Degree of differentiation of inputs
3.6.4.2 Supplier concentration to firm concentration ratio
3.6.4.3 Supplier switching costs relative to firm switching costs
3.6.5 Intensity of Competitive Rivalry
3.6.5.1 Number of competitors
3.6.5.2 Diversity of competitors
3.6.5.3 Industry concentration
3.6.5.4 Industry growth
3.6.5.5 Quality differences

4. Global Spinal Muscular Atrophy (SMA) Market - By Disease
4.1 Type 1
4.1.1 Market size and forecast, 2020-2030 (USD Million)
4.2 Type 2
4.2.1 Market size and forecast, 2020-2030 (USD Million)
4.3 Type 3
4.3.1 Market size and forecast, 2020-2030 (USD Million)
4.4 Type 4
4.4.1 Market size and forecast, 2020-2030 (USD Million)

5. Global Spinal Muscular Atrophy (SMA) Market - By Treatment
5.1 Gene therapy
5.1.1 Market size and forecast, 2020-2030 (USD Million)
5.2 Drug
5.2.1 Market size and forecast, 2020-2030 (USD Million)

6. Global Spinal Muscular Atrophy (SMA) Market - By Route of Administration
6.1 Oral
6.1.1 Market size and forecast, 2020-2030 (USD Million)
6.2 Intrathecal
6.2.1 Market size and forecast, 2020-2030 (USD Million)

7. By Region
7.1 Introduction
7.2 North America Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Million)
7.2.1 U.S.
7.2.1.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.2.1.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.2.1.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.2.2 Canada
7.2.2.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.2.2.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.2.2.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3 Europe Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Million)
7.3.1 Germany
7.3.1.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.1.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.1.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.2 France
7.3.2.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.2.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.2.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.3 UK
7.3.3.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.3.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.3.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.4 Italy
7.3.4.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.4.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.4.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.5 Spain
7.3.5.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.5.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.5.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.6 Russia
7.3.6.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.6.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.6.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.3.7 Rest of Europe
7.3.7.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.3.7.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.3.7.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Million)
7.4.1 Japan
7.4.1.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.1.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.1.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4.2 China
7.4.2.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.2.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.2.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4.3 India
7.4.3.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.3.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.3.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4.4 Australia
7.4.4.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.4.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.4.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4.5 ASEAN
7.4.5.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.5.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.5.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.4.6 Rest of APAC
7.4.6.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.4.6.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.4.6.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.5 Latin America Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Million)
7.5.1 Brazil
7.5.1.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.5.1.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.5.1.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.5.2 Mexico
7.5.2.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.5.2.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.5.2.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.5.3 Rest of Latin America
7.5.3.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.5.3.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.5.3.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.6 Middle East Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Million)
7.6.1 UAE
7.6.1.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.6.1.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.6.1.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.6.2 Saudi Arabia
7.6.2.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.6.2.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.6.2.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.6.3 South Africa
7.6.3.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.6.3.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.6.3.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)
7.6.4 RoMEA
7.6.4.1 Market Size & Forecast, By Disease, 2020-2030 (USD Million)
7.6.4.2 Market Size & Forecast, By Treatment, 2020-2030 (USD Million)
7.6.4.3 Market Size & Forecast, By Route of Administration, 2020-2030 (USD Million)

8. Competitive Landscape
8.1 Competitive environment
8.2 New product development
8.3 Merger & acquisitions
8.4 Strategic framework

9. Leading Companies
9.1 Avexis, Inc.
9.1.1 Company Overview
9.1.2 Product Offerings
9.1.3 Financial Performance (2016-2018)
9.1.4 Recent Initiatives
9.1.5 SWOT Analysis
9.2 Biogen
9.2.1 Company Overview
9.2.2 Product Offerings
9.2.3 Financial Performance (2016-2018)
9.2.4 Recent Initiatives
9.2.5 SWOT Analysis
9.3 Biogen
9.3.1 Company Overview
9.3.2 Product Offerings
9.3.3 Financial Performance (2016-2018)
9.3.4 Recent Initiatives
9.3.5 SWOT Analysis
9.4 Boehringer Ingelheim GmbH
9.4.1 Company Overview
9.4.2 Product Offerings
9.4.3 Financial Performance (2016-2018)
9.4.4 Recent Initiatives
9.4.5 SWOT Analysis
9.5 Cytokinetics, Inc.
9.5.1 Company Overview
9.5.2 Product Offerings
9.5.3 Financial Performance (2016-2018)
9.5.4 Recent Initiatives
9.5.5 SWOT Analysis
9.6 F. Hoffmann-La Roche AG
9.6.1 Company Overview
9.6.2 Product Offerings
9.6.3 Financial Performance (2016-2018)
9.6.4 Recent Initiatives
9.6.5 SWOT Analysis
9.7 Ionis Pharmaceuticals, Inc.
9.7.1 Company Overview
9.7.2 Product Offerings
9.7.3 Financial Performance (2016-2018)
9.7.4 Recent Initiatives
9.7.5 SWOT Analysis
9.8 Isis Pharmaceuticals, Inc.
9.8.1 Company Overview
9.8.2 Product Offerings
9.8.3 Financial Performance (2016-2018)
9.8.4 Recent Initiatives
9.8.5 SWOT Analysis
9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Product Offerings
9.9.3 Financial Performance (2016-2018)
9.9.4 Recent Initiatives
9.9.5 SWOT Analysis
9.10 Pfizer, Inc.
9.10.1 Company Overview
9.10.2 Product Offerings
9.10.3 Financial Performance (2016-2018)
9.10.4 Recent Initiatives
9.10.5 SWOT Analysis
9.11 Regeneron Pharmaceuticals, Inc.
9.11.1 Company Overview
9.11.2 Product Offerings
9.11.3 Financial Performance (2016-2018)
9.11.4 Recent Initiatives
9.11.5 SWOT Analysis

10. Appendix
10.1 Insights of Industry Experts
10.2 Related Reports
10.3 Author Details
10.4 Available Customizations

LIST OF TABLES
Table 1 Global Spinal Muscular Atrophy (SMA) Market Size, By Region, 2020-2030 (USD Mn, CAGR%)
Table 2 Global Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 3 Global Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 4 Global Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 5 North America: Spinal Muscular Atrophy (SMA) Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 6 North America: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 7 North America: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 8 North America: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 9 US: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 10 US: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 11 US: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 12 Canada: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 13 Canada: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 14 Canada: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 15 Europe: Spinal Muscular Atrophy (SMA) Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 16 Europe: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 17 Europe: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 18 Europe: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 19 Germany: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 20 Germany: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 21 Germany: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 22 France: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 23 France: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 24 France: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 25 UK: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 26 UK: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 27 UK: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 28 Italy: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 29 Italy: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 30 Italy: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 31 Spain: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 32 Spain: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 33 Spain: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 34 Russia: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 35 Russia: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 36 Russia: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 37 Rest of Europe: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 38 Rest of Europe: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 39 Rest of Europe: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 40 Asia-Pacific: Spinal Muscular Atrophy (SMA) Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 41 Asia-Pacific: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 42 Asia-Pacific: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 43 Asia-Pacific: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 44 Japan: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 45 Japan: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 46 Japan: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 47 China: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 48 China: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 49 China: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 50 India: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 51 India: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 52 India: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 53 Australia: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 54 Australia: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 55 Australia: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 56 ASEAN: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 57 ASEAN: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 58 ASEAN: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 59 Rest of APAC: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 60 Rest of APAC: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 61 Rest of APAC: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 62 Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 63 Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 64 Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 65 Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 66 Brazil: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 67 Brazil: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 68 Brazil: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 69 Mexico: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 70 Mexico: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 71 Mexico: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 72 Rest of Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 73 Rest of Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 74 Rest of Latin America: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 75 MEA: Spinal Muscular Atrophy (SMA) Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 76 MEA: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 77 MEA: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 78 MEA: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 79 UAE: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 80 UAE: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 81 UAE: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 82 Saudi Arabia: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 83 Saudi Arabia: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 84 Saudi Arabia: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 85 South Africa: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 86 South Africa: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 87 South Africa: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)
Table 88 Rest of MEA: Spinal Muscular Atrophy (SMA) Market Size, By Disease, 2020-2030 (USD Mn, CAGR%)
Table 89 Rest of MEA: Spinal Muscular Atrophy (SMA) Market Size, By Treatment, 2020-2030 (USD Mn, CAGR%)
Table 90 Rest of MEA: Spinal Muscular Atrophy (SMA) Market Size, By Route of Administration, 2020-2030 (USD Mn, CAGR%)

LIST OF FIGURES
Figure 1 Global Spinal Muscular Atrophy (SMA) Market Segmentation
Figure 2 Global Spinal Muscular Atrophy (SMA) Market: Market Dynamics
Figure 3 Global Spinal Muscular Atrophy (SMA) Market Porter's analysis
Figure 4 Global Spinal Muscular Atrophy (SMA) Market PEST analysis
Figure 5 Drivers, Restraints, Opportunities, and Challenges in the Global Spinal Muscular Atrophy (SMA) Market
Figure 6 Global Spinal Muscular Atrophy (SMA) Market, By Disease, 2020-2030 (USD Mn)
Figure 7 Global Spinal Muscular Atrophy (SMA) Market, By Treatment, 2020-2030 (USD Mn)
Figure 8 Global Spinal Muscular Atrophy (SMA) Market, By Route of Administration, 2020-2030 (USD Mn)
Figure 9 Global Spinal Muscular Atrophy (SMA) Market, By Region, 2018 & 2030 (%)
Figure 10 North America Spinal Muscular Atrophy (SMA) Market, By Country, 2018 & 2030 (%)
Figure 11 U.S. Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 12 Canada Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 13 Europe Spinal Muscular Atrophy (SMA) Market, By Country, 2018 & 2030 (%)
Figure 14 Germany Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 15 UK Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 16 France Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 17 Italy Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 18 Spain Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 19 Russia Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 20 Rest of Europe Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 21 APAC Spinal Muscular Atrophy (SMA) Market, By Country, 2018 & 2030 (%)
Figure 22 Japan Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 23 China Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 24 Australia Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 25 ASEAN Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 26 Rest of APAC Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 27 Latin America Spinal Muscular Atrophy (SMA) Market, By Country, 2018 & 2030 (%)
Figure 28 Brazil Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 29 Mexico Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 30 Rest of Latin America Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 31 MEA Spinal Muscular Atrophy (SMA) Market, By Country, 2018 & 2030 (%)
Figure 32 UAE Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 33 Saudi Arabia Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 34 South Africa Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 35 Rest of MEA Spinal Muscular Atrophy (SMA) Market, 2020-2030 (USD Mn)
Figure 36 Company Share Analysis, 2018
Figure 37 Recent Development: 2016-2018
Figure 38 Global Spinal Muscular Atrophy (SMA) Market Concentration Rate
Figure 39 SWOT Analysis: Avexis, Inc.
Figure 40 SWOT Analysis: Biogen
Figure 41 SWOT Analysis: Boehringer Ingelheim GmbH
Figure 42 SWOT Analysis: Cytokinetics, Inc.
Figure 43 SWOT Analysis: F. Hoffmann-La Roche AG
Figure 44 SWOT Analysis: Ionis Pharmaceuticals, Inc.
Figure 45 SWOT Analysis: Isis Pharmaceuticals, Inc.
Figure 46 SWOT Analysis: Novartis AG
Figure 47 SWOT Analysis: Pfizer, Inc.
Figure 48 SWOT Analysis: Regeneron Pharmaceuticals, Inc.

Avexis, Inc.
Biogen
Biogen
Boehringer Ingelheim GmbH
Cytokinetics, Inc.
F. Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Novartis AG
Pfizer, Inc.
Regeneron Pharmaceuticals, Inc.